TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03261986

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiostereometric Analysis
Description: RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: total hip arthroplasty with RSA bead implantation
Description: Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
Study: NCT02293889

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000IU/daily 3 months
Description: Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000IU/daily 3 months
Description: Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA intervention People with Osteoarthritis Walking Programme
Description: The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA intervention People with Osteoarthritis Walking Programme
Description: The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule (Vitamin D): edible oil
Description: Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
Study: NCT02235090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct current stimulation of cervical spinal cord
Description: 10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct current stimulation of cervical spinal cord
Description: 10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Direct current stimulation of cervical spinal cord
Description: 10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
Study: NCT06020287

Intervention type: PROCEDURE
Intervention: the robot-assisted laparoscopic radical prostatectomy
Description: We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.

Intervention type: PROCEDURE
Intervention: the robot-assisted laparoscopic radical prostatectomy
Description: We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.

Intervention type: PROCEDURE
Intervention: the robot-assisted laparoscopic radical prostatectomy
Description: We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
Study: NCT04576299

Intervention type: OTHER
Intervention: Group 1
Description: Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
Study: NCT00460135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: 2 times a week resistance training
Study: NCT03757260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy
Description: Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of photodynamic therapy
Description: The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
Study: NCT01425320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination dapsone/adapalene Formulation A Gel
Description: Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination dapsone/adapalene Formulation B Gel
Description: Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapsone 5% gel
Description: Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene 0.3% gel
Description: Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
Study: NCT04258293

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
Study: NCT01083225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client feedback
Description: Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual, consultations
Study: NCT00966680

Intervention type: OTHER
Intervention: Anesthesia
Description: How long anesthesiologists take to administer general and spinal anesthesia.
Study: NCT01678313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
Description: Study group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg every day (QD)
Description: Control group
Study: NCT03949361

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET
Description: Dynamic PET scanning of the neck-region

Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary glucose
Description: Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
Study: NCT04831268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trahanas with tomato sauce mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trahanas with tomato sauce mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trahanas with tomato sauce mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trahanas with tomato sauce mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT03949361

Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary glucose
Description: Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy of supraclavicular adipose tissue (optional)
Description: Ultrasound guided biopsy of the supraclavicular adipose tissue

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy of supraclavicular adipose tissue (optional)
Description: Ultrasound guided biopsy of the supraclavicular adipose tissue
Study: NCT01083368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03971097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six Step Model of Self-Forgiveness
Description: The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process.
Study: NCT04831268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halva with currants mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT03971097

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
Study: NCT04831268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halva with currants mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halva with currants mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halva with currants mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT01365013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DE-PLAN
Description: structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard advice for lifestyle change
Study: NCT03478462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 131
Description: IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Study: NCT04419662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of PEEP and positioning
Description: Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees.
Study: NCT02204397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP Peptide, Ustekinumab
Study: NCT00678236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refobacin Bone Cement R
Description: Insertion of a knee prosthesis fixed by Refobacin Bone Cement R

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refobacin Plus Bone Cement
Description: Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
Study: NCT04314609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography, fluoroscopy
Description: success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
Study: NCT00804674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01516437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swab collection
Description: Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swab collection
Description: Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swab collection
Description: Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swab collection
Description: Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum collection
Description: Sputum collection at Day 0 and at exacerbation visits (COPD subjects)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum collection
Description: Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
Study: NCT00217620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 800 mg per day, daily until progression
Study: NCT01622504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVP005
Description: 2 mg single dose administered intranasally
Study: NCT02892305

Intervention type: PROCEDURE
Intervention: Hepatic Resection or Ablation with Pancreaticoduodenectomy
Description: Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care.
Study: NCT00997555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopy
Description: Scheduled bronchoscopy.
Study: NCT01622504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVP005
Description: 4 mg single dose administered intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride solution for injection with mucosal atomization device
Description: 2 mg single dose administered intranasally
Study: NCT01535547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study: NCT03281577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 IV infusion.
Study: NCT01398215

Intervention type: PROCEDURE
Intervention: transvaginal NOTES ventral hernia repair
Description: ventral hernia repair via the transvaginal approach
Study: NCT02627248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: 20g tid, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: 20g tid, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 70 mg/m² ivdrip, d1 for both TEC and ET regimes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 70 mg/m² ivdrip, d1 for both TEC and ET regimes
Study: NCT03281577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-954 placebo-matching IV infusion.
Study: NCT01709513

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab, ezitimibe and atorvastatin.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo for alirocumab, ezitimibe and atorvastatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab, ezitimibe and atorvastatin.
Study: NCT04460365

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin
Description: This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel capsule containing sunflower oil (no active ingredients)